Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
Kudo M, Ueshima K, Saeki I, Ishikawa T, Inaba Y, Morimoto N, Aikata H, Tanabe N, Wada Y, Kondo Y, Tsuda M, Nakao K, Ito T, Hosaka T, Kawamura Y, Kuzuya T, Nojiri S, Ogawa C, Koga H, Hino K, Ikeda M, Moriguchi M, Hisai T, Yoshimura K, Furuse J, Arai Y. Kudo M, et al. Among authors: inaba y. Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb. Liver Cancer. 2023. PMID: 38344448 Free PMC article.
Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan.
Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y, Yabushita K, Motoyoshi K, Kudo M. Furuse J, et al. Among authors: inaba y. Drugs Real World Outcomes. 2023 Jun;10(2):195-205. doi: 10.1007/s40801-022-00348-w. Epub 2023 Jan 5. Drugs Real World Outcomes. 2023. PMID: 36602748 Free PMC article.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Protocol for a confirmatory trial of the effectiveness and safety of palliative arterial embolization for painful bone metastases.
Zenda S, Arai Y, Sugawara S, Inaba Y, Hashimoto K, Yamamoto K, Saigusa Y, Kawaguchi T, Shimada S, Yokoyama M, Miyaji T, Okano T, Nakamura N, Kobayashi E, Takagi T, Matsumoto Y, Uchitomi Y, Sone M; J-SUPPORT 1903, PALEM Trial. Zenda S, et al. Among authors: inaba y. BMC Cancer. 2023 Jan 31;23(1):109. doi: 10.1186/s12885-023-10538-6. BMC Cancer. 2023. PMID: 36721103 Free PMC article.
Clinical Outcomes of Radiofrequency Ablation Combined with Transarterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Non-hepatocellular Carcinoma Malignant Liver Tumors.
Yoshihara T, Hasegawa T, Sato Y, Yamaura H, Murata S, Chatani S, Tsukii R, Nagasawa K, Tsushima Y, Inaba Y. Yoshihara T, et al. Among authors: inaba y. Interv Radiol (Higashimatsuyama). 2023 Mar 1;8(1):7-13. doi: 10.22575/interventionalradiology.2022-0017. eCollection 2023 Mar 1. Interv Radiol (Higashimatsuyama). 2023. PMID: 36936255 Free PMC article.
Percutaneous Radiofrequency Ablation for Liver Tumors: Technical Tips.
Sato Y, Hasegawa T, Chatani S, Murata S, Inaba Y. Sato Y, et al. Among authors: inaba y. Interv Radiol (Higashimatsuyama). 2020 Jun 30;5(2):50-57. doi: 10.22575/interventionalradiology.2020-0008. eCollection 2020 Jun 30. Interv Radiol (Higashimatsuyama). 2020. PMID: 36284662 Free PMC article. Review.
Novel Ureteral Stent Catheterization Technique for Treating Hyperchloremic Metabolic Acidosis After Total Pelvic Exenteration.
Komori K, Tanaka T, Inaba Y, Kinoshita T, Sato Y, Ouchi A, Ito S, Abe T, Misawa K, Ito Y, Natsume S, Higaki E, Asano T, Okuno M, Fujieda H, Akaza S, Saito H, Narita K, Kitahara T, Hanazawa T, Ojio H, Negita M, Shimizu Y. Komori K, et al. Among authors: inaba y. Anticancer Res. 2023 Nov;43(11):5149-5153. doi: 10.21873/anticanres.16715. Anticancer Res. 2023. PMID: 37909985
1,571 results